Marc F. Giovannini

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Marine Gilabert · 15 shared papers, 2012–2021 · strength 0.99
   • Paper Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regime… DOI 10.1016/j.ejso.2020.02.037↗
   • Paper Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic duc… DOI 10.1016/j.pan.2019.12.001↗
   • Paper Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a pr… DOI 10.1186/s12885-020-6690-1↗
2. Olivıer Turrini · 15 shared papers, 2011–2020 · strength 0.90
   • Paper Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regime… DOI 10.1016/j.ejso.2020.02.037↗
   • Paper Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic duc… DOI 10.1016/j.pan.2019.12.001↗
   • Paper Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a pr… DOI 10.1186/s12885-020-6690-1↗
3. Juan Iovanna · 12 shared papers, 2011–2023 · strength 0.77
   • Paper A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma. DOI 10.1053/j.gastro.2022.11.035↗
   • Paper Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict a… DOI 10.1016/j.tranon.2021.101315↗
   • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
4. Jean‐Robert Delpéro · 11 shared papers, 2011–2020 · strength 0.71
   • Paper Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regime… DOI 10.1016/j.ejso.2020.02.037↗
   • Paper Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic duc… DOI 10.1016/j.pan.2019.12.001↗
   • Paper Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a pr… DOI 10.1186/s12885-020-6690-1↗
5. Nelson Dusetti · 10 shared papers, 2015–2023 · strength 0.69
   • Paper A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma. DOI 10.1053/j.gastro.2022.11.035↗
   • Paper Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict a… DOI 10.1016/j.tranon.2021.101315↗
   • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
6. Rémy Nicolle · 7 shared papers, 2017–2023 · strength 0.57
   • Paper A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma. DOI 10.1053/j.gastro.2022.11.035↗
   • Paper Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict a… DOI 10.1016/j.tranon.2021.101315↗
   • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
7. Odile Gayet · 9 shared papers, 2015–2022 · strength 0.55
   • Paper Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict a… DOI 10.1016/j.tranon.2021.101315↗
   • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
   • Paper Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic… DOI 10.1016/j.ebiom.2020.102858↗
8. Jonathan Garnier · 6 shared papers, 2016–2020 · strength 0.51
   • Paper Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regime… DOI 10.1016/j.ejso.2020.02.037↗
   • Paper Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic duc… DOI 10.1016/j.pan.2019.12.001↗
   • Paper Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a pr… DOI 10.1186/s12885-020-6690-1↗
9. Pauline Duconseil · 8 shared papers, 2015–2021 · strength 0.47
   • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
   • Paper Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. DOI 10.1186/s12957-019-1637-1↗
   • Paper Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic… DOI 10.1016/j.ebiom.2020.102858↗
10. Ugo Marchèse · 4 shared papers, 2019–2020 · strength 0.42
    • Paper Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regime… DOI 10.1016/j.ejso.2020.02.037↗
    • Paper Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic duc… DOI 10.1016/j.pan.2019.12.001↗
    • Paper Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a pr… DOI 10.1186/s12885-020-6690-1↗
11. Laurence Moureau-Zabotto · 5 shared papers, 2012–2020 · strength 0.40
    • Paper Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regime… DOI 10.1016/j.ejso.2020.02.037↗
    • Paper Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a pr… DOI 10.1186/s12885-020-6690-1↗
    • Paper Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. DOI 10.1186/s12957-019-1637-1↗
12. Jean‐Luc Raoul · 8 shared papers, 2012–2017 · strength 0.36
    • Paper Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients. DOI 10.1007/s12029-015-9774-4↗
    • Paper Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a ca… DOI 10.18632/oncotarget.9861↗
    • Paper Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma. PMID 27107061↗
13. Julie Roques · 4 shared papers, 2017–2022 · strength 0.33
    • Paper Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict a… DOI 10.1016/j.tranon.2021.101315↗
    • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
    • Paper Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic… DOI 10.1016/j.ebiom.2020.102858↗
14. Jerome F. Cros · 3 shared papers, 2020–2022 · strength 0.29
    • Paper Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict a… DOI 10.1016/j.tranon.2021.101315↗
    • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
    • Paper Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic… DOI 10.1016/j.ebiom.2020.102858↗
15. Véronique Secq · 6 shared papers, 2015–2018 · strength 0.26
    • Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
    • Paper Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain i… DOI 10.15252/emmm.201606975↗
    • Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
16. Emmanuel Mitry · 2 shared papers, 2022–2023 · strength 0.26
    • Paper A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma. DOI 10.1053/j.gastro.2022.11.035↗
    • Paper Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict a… DOI 10.1016/j.tranon.2021.101315↗
17. Brice Chanez · 2 shared papers, 2022–2023 · strength 0.26
    • Paper A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma. DOI 10.1053/j.gastro.2022.11.035↗
    • Paper Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict a… DOI 10.1016/j.tranon.2021.101315↗
18. Laëtitia Dahan · 3 shared papers, 2012–2022 · strength 0.23
    • Paper Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict a… DOI 10.1016/j.tranon.2021.101315↗
    • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
    • Paper BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus place… DOI 10.1093/annonc/mds135↗
19. Magali Svrcek · 2 shared papers, 2021–2022 · strength 0.21
    • Paper Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict a… DOI 10.1016/j.tranon.2021.101315↗
    • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
20. Jean‐Luc Van Laethem · 2 shared papers, 2021–2022 · strength 0.21
    • Paper Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict a… DOI 10.1016/j.tranon.2021.101315↗
    • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
21. Francesco Puleo · 2 shared papers, 2021–2022 · strength 0.21
    • Paper Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict a… DOI 10.1016/j.tranon.2021.101315↗
    • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
22. Pascal R. Hammel · 2 shared papers, 2021–2022 · strength 0.21
    • Paper Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict a… DOI 10.1016/j.tranon.2021.101315↗
    • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
23. Jean‐Baptiste Bachet · 2 shared papers, 2021–2022 · strength 0.21
    • Paper Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict a… DOI 10.1016/j.tranon.2021.101315↗
    • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
24. Tatjana Arsenijevic · 2 shared papers, 2021–2022 · strength 0.21
    • Paper Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict a… DOI 10.1016/j.tranon.2021.101315↗
    • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
25. Céline Loncle · 5 shared papers, 2015–2017 · strength 0.21
    • Paper Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain i… DOI 10.15252/emmm.201606975↗
    • Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
    • Paper A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. DOI 10.18632/oncotarget.10776↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.